GlassScriptPhysician profile
Denisse M Serrano
NPI 1578914313
$255,170.90
in general payments reported to CMS, 2019-2025
17 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23K · 2022: $48K · 2023: $72K · 2024: $84K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $146K · Travel and Lodging: $18K · Consulting Fee: $12K · Food and Beverage: $7,218 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $145,930.00 |
| Travel and Lodging | $18,229.00 |
| Consulting Fee | $12,060.00 |
| Food and Beverage | $7,217.54 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $130,583.91 | 2021-2025 | |
| Galderma Laboratories, L.P. | $71,523.33 | 2022-2025 | Epsolay, Dysport |
| Allergan, INC. | $50,765.39 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $1,050.99 | 2021-2023 | Absorica Ld, Winlevi |
| Merz North America, INC. | $466.42 | 2021-2023 | |
| Janssen Biotech, INC. | $188.74 | 2021-2023 | Tremfya |
| Journey Medical Corporation | $114.27 | 2023 | |
| Amgen INC. | $104.38 | 2021-2023 | Otezla |
| Incyte Corporation | $86.37 | 2021-2023 | Opzelura |
| Genzyme Corporation | $67.60 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $59.78 | 2023 | Sotyktu |
| Almirall LLC | $48.51 | 2021-2022 | |
| Lilly USA, LLC | $27.39 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $25.49 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.08 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $20.25 | 2021 | |
| Revance Therapeutics, INC. | $14.00 | 2024 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denisse Serrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.